1294519-55-3

Upstream product

• 121-52-8 3-nitrophenylsulfonamide 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 1294519-72-4 C₁₂H₁₂N₂O₂S 
• 1294519-73-5 C₁₃H₁₄N₂O₂S 
• 1294519-74-6 C₁₂H₁₁FN₂O₂S 
• 1294519-83-7 C₁₁H₁₁N₃O₂S 
• 1294519-75-7 C₁₂H₁₃N₃O₃S 
• 1294519-76-8 C₁₁H₁₁N₃O₂S 
• 1294519-77-9 C₁₀H₁₀N₄O₂S 
• 1294519-78-0 C₁₀H₁₀N₄O₂S 
• 1294519-79-1 C₁₁H₁₂N₄O₂S 
• 1294519-80-4 C₁₅H₁₃N₃O₂S 
• 1294519-81-5 C₁₄H₁₄N₄O₂S 
• 1294519-82-6 C₁₀H₁₀N₂O₂S₂ 

Relevant academic research and scientific papers

A general route to unsubstituted N-aryl and heteroarylaminobenzenesulfonamides

Starting from suitably protected 3- and 4-aminobenzenesulfonamides, a practical two-step strategy for the synthesis of unsubstituted N-aryl and heteroarylaminobenzenesulfonamides was devised. Strong bases are tolerated during the N-arylation step. Overall moderate to excellent yields are reported.

5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.